Nonoxynol-9 100 mg gel: Multi-site safety study from sub-Saharan Africa

Irving F. Hoffman, Taha E Taha, Nancy S. Padian, Clifton W. Kelly, Julia D. Welch, Francis E. Martinson, Newton I. Kumwenda, Zeda F. Rosenberg, David A. Chilongozi, Joelle M. Brown, Michael Chirenje, Barbra A. Richardson

Research output: Contribution to journalArticle


Objectives: To evaluate the safety of 100mg nonoxynol-9 (N-9) gel, a vaginal microbicide, on the genital mucosa of women from Malawi and Zimbabwe in preparation for a phase III efficacy study. Methods: HIV-uninfected women (180) were enrolled and randomized to either N-9 or placebo gel and instructed to insert gel into the vagina twice daily for 14 days. Follow up examinations were conducted at 7 and 14 days. Results: The number of adverse events in the N-9 gel group was higher than in the placebo group (40% versus 13%; P

Original languageEnglish (US)
Pages (from-to)2191-2195
Number of pages5
Issue number16
Publication statusPublished - Nov 5 2004



  • Genital ulcers
  • HIV
  • Nonoxynol-9
  • Safety
  • Vaginal microbicide

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Hoffman, I. F., Taha, T. E., Padian, N. S., Kelly, C. W., Welch, J. D., Martinson, F. E., ... Richardson, B. A. (2004). Nonoxynol-9 100 mg gel: Multi-site safety study from sub-Saharan Africa. AIDS, 18(16), 2191-2195.